NCT05188508 2026-03-06
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT02658279 2026-03-03
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT04977375 2025-09-03
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1/2 Recruiting
NCT02311582 2025-05-29
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Washington University School of Medicine
Phase 1/2 Completed
NCT02960230 2025-01-22
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
University of California, San Francisco
Phase 1/2 Completed
NCT06640582 2024-11-05
BAH2472
Essen Biotech
Phase 1/2 Recruiting
NCT02313272 2023-10-23
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04220892 2020-07-31
Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
Saint John's Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT03311542 2018-01-10
Expanded Access for Pembrolizumab (MK-3475)
Center Trials & Treatment
No longer available